The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
HOME > BUSINESS
BUSINESS
- Ribomic Aims to Commercialize Non-Addictive Analgesic Nucleic Acid Drug
August 30, 2012
- Takeda to Start Local Manufacturing at New Russian Factory around FY2014
August 30, 2012
- IBL, IBR to Codevelop Vaccines Using Transgenic Silkworms
August 30, 2012
- Torii to Exclusively Market JT’s Novel Anti-HIV Drug in Japan
August 30, 2012
- GSK Launches ReQuip CR Tablets; MHLW Recommends Use
August 30, 2012
- Takeda Less Dependent on Japan, US Revenues Due to Expanding Emerging Market Biz: CCO Morich
August 29, 2012
- Takeda Gearing Up for Emerging Market Operations
August 29, 2012
- MTPC, Daiichi Sankyo to Launch DPP-4 Inhibitor Tenelia on Sept. 10
August 29, 2012
- Izumo, Former VP of Novartis Institutes for BioMedical Research, Appointed Head of Takeda’s MD Drug Discovery Unit
August 29, 2012
- JT’s Licensee Obtains US Approval for Combination Tablet Containing JTK-303
August 29, 2012
- Nichi-Iko Voluntarily Recalls Lansoprazole OD Tablets 15 mg
August 29, 2012
- Daiichi Sankyo, Eli Lilly Not to Apply for Prasugrel for ACS in the US, Europe
August 29, 2012
- Major US, European Pharmaceutical Makers Faced with “Patent Cliffs”
August 28, 2012
- Plavix Approved for STEMI: sanofi-aventis
August 28, 2012
- Strattera Approved as 1st Adult ADHD Treatment in Japan: Eli Lilly Japan
August 28, 2012
- Growject Approved for SGA Dwarfism: JCR
August 28, 2012
- Large Portfolio, Competitive Prices, High Quality to Be Key to Success in Generics Business: Mr Bourla of Pfizer
August 27, 2012
- Japanese Ethical Drug Market Expands by 2.1% in Apr-Jun 2012: IMS Japan
August 27, 2012
- Diovan Approved for Pediatric Hypertension; Japan’s 1st ARB Approved for Pediatric Indication: Novartis
August 27, 2012
- Kyowa Kirin Initiates PII trial of Mogamulizumab in Europe, the US
August 27, 2012
ページ
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…